Angiogenin up-regulation correlates with adverse clinicopathological and biological factors, increased microvascular density and poor patient outcome in neuroblastomas
- 28 February 2012
- journal article
- Published by Wiley in Histopathology
- Vol. 60 (6) , 911-923
Abstract
As new biomarkers are urgently needed to identify children with high-risk neuroblastoma (NB), we studied the contribution of angiogenin (ANG) to angiogenesis and its association with clinicopathological and biological features and patient outcome in NB. Ninety NBs and 12 ganglioneuromas (GNs) were immunostained for ANG and CD31. ANG expression in NB tumoral cells (ANG scores) and vessels [ANG microvascular density (MVD)] and total MVD (CD31 MVD) were determined. The ANG score was significantly greater in NBs than in GNs (P = 0.015) and in NBs from children with stage 4 tumours, high-risk disease, unfavourable pathology (P < 0.001 for each), MYCN amplification (P = 0.003), and 1p deletion (P = 0.002). ANG scores correlated with ANG MVD and CD31 MVD (P < 0.001 for each). Total ANG and CD31 protein levels, measured with a sensitive enzyme-linked immunosorbent assay, were highly correlated (P = 0.003). High ANG scores were associated with decreased overall and event-free survival (log-rank test, P = 0.025 and P = 0.018, respectively). High ANG MVD was associated with decreased overall and event-free survival (log-rank test, P = 0.009 and P = 0.026, respectively). High CD31 MVD was associated with decreased event-free survival (P = 0.045). The strong correlation of ANG up-regulation with total MVD and adverse clinicopathological and biological factors indicates that ANG supports growth and progression in NB.Keywords
This publication has 40 references indexed in Scilit:
- Balance of pro‐ versus anti‐angiogenic splice isoforms of vascular endothelial growth factor as a regulator of neuroblastoma growthThe Journal of Pathology, 2010
- Molecular pathogenesis of peripheral neuroblastic tumorsOncogene, 2010
- Recent advances in targeted anti-vasculature therapy: the neuroblastoma model.Current Drug Targets, 2009
- Bevacizumab suppresses neuroblastoma progression in the setting of minimal diseaseSurgery, 2008
- Angiogenesis as a target in neuroblastomaEuropean Journal of Cancer, 2008
- Mechanisms of action of angiogeninActa Biochimica et Biophysica Sinica, 2008
- Initial testing (stage 1) of sunitinib by the pediatric preclinical testing programPediatric Blood & Cancer, 2008
- Initial testing of the VEGFR inhibitor AZD2171 by the pediatric preclinical testing programPediatric Blood & Cancer, 2008
- Amino acid sequence of human tumor derived angiogeninBiochemistry, 1985
- Isolation and characterization of angiogenin, an angiogenic protein from human carcinoma cellsBiochemistry, 1985